Skip to main content
Clinical Trials/NCT01481961
NCT01481961
Completed
Not Applicable

Feasibility Study: Cognitive Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)on add-on in Patients With Early Alzheimer's Disease

Pierre Vandel, MD PhD1 site in 1 country15 target enrollmentNovember 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alzheimer's Disease
Sponsor
Pierre Vandel, MD PhD
Enrollment
15
Locations
1
Primary Endpoint
changes in MMSE (Mini Mental State Examination)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The aim is to examine the effect of Repetitive Transcranial Magnetic Stimulation (rTMS) applied at the anodic left Cortex DorsoLateral PreFrontal (CDLPF) of patients with early Alzheimer's disease (AD).

This study included 15 patients treated with rTMS and whose medication reference is stabilized for 3 months by IAChE. Patients with early AD or related disease will be selected in the MCRR of Besançon and the psychiatric department of the University Hospital of Besançon. After giving informed consent, patients will be evaluated by a psychiatrist using the Mattis Clinical Demantia Rate (CDR), the Hamilton Depression Rating Scale (HDRS), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI) and Hamilton Anxiety Scale (HAMA). The complete assessment takes 40 minutes. A second evaluation will be realized by a neuropsychologist takes around 120 minutes using Mattis CDR, Grober Free and Cued Selective Reminding Test, Trail Making Test (TMT), Crossing of Test (COT), Isaacs Set Test (STI) , Clock-Drawing Test (COT), Signoret's Battery of Cognitive Efficacy (BEC96), Rey-complex figure test-copy and Picture naming 80 items test (DO80).

Each rTMS session runs 20 minutes during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session) will be delivered. A psychometric assessment will be conducted again at the end of treatment week and one month after stopping treatment. A neuropsychometric assessment will be conducted one month after stopping the treatment. Scales of comfort and acceptability will also be proposed to the patient to determine whether any gene is caused by this treatment. Moreover a questionnaire will be proposed to the caregivers (at baseline, at the end of the treatment and 1, 2, 3 and 4 weeks after stopping the sessions) using Resource Utilisation Dementia (RUD), Apathy Inventory (AI), Activities of Daily Living (ADL) scale, Instrumental Activities of Daily Living (IADL) scale, Quality of Life in Alzheimer's disease (QoL-AD) scale, Questionnaire of recent change of the personality (CP6).

The population of this study will be comprised of patients between 60 to 85 years-old with early Alzheimer's characterized according to NINCDS-ADRADA criteria. These patients will be recruited on a voluntary basis, after notification and consent in the research center. This study was conducted over a period of 15 months.

Registry
clinicaltrials.gov
Start Date
November 2010
End Date
May 2012
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Pierre Vandel, MD PhD
Responsible Party
Sponsor Investigator
Principal Investigator

Pierre Vandel, MD PhD

PU PH

Centre Hospitalier Universitaire de Besancon

Eligibility Criteria

Inclusion Criteria

  • subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.
  • subject under treatment by IAChE for at least 3 months.
  • CDR score ≤ 2
  • psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months

Exclusion Criteria

  • subjects diagnosed with psychiatric disorder (depression according to DSM-IV criteria, bipolar disorder, schizophrenia, addiction)

Outcomes

Primary Outcomes

changes in MMSE (Mini Mental State Examination)

Time Frame: baseline, 1wk, 4wk

The changes in MMSE will constitute the major research outcome measure used to assess response to rTMS.

Secondary Outcomes

  • changes in HDRS (Hamilton Depression Rating Scale)(baseline, 1wk, 4wk)
  • changes in STAI (State-Trait Anxiety Inventory)(baseline, 1wk, 4wk)
  • changes in BDI (Beck Depression Inventory)(baseline, 1wk, 4 wk)
  • changes in HAMA (Hamilton Anxiety Scale)(baseline, 1 wk, 4 wk)
  • changes in Mattis DRS (Dementia Rating Scale)(baseline, 1 wk, 4 wk)
  • changes in CDR (Clinical Dementia Rate)(baseline, 1 wk, 4 wk)
  • changes in Grober Free and Cued Selective Reminding Test(baseline, 4 wk)
  • changes in TMT (Trail Making Test)(baseline, 4 wk)
  • changes in COT (Crossing Of Test)(baseline, 4 wk)
  • changes in IST (Isaacs Set Test)(baseline, 4 wk)
  • changes in CDT (Clock-Drawing Test)(baseline, 4 wk)
  • changes in Signoret's Battery of Cognitive Efficacy (BEC96)(baseline, 4 wk)
  • changes in Rey-complex figure test-copy(baseline, 4 wk)
  • changes in Picture naming 80 items test (DO80)(baseline, 4 wk)
  • changes in RUD (Resource Utilisation Dementia)(baseline, at the end of treatment, 1wk, 2 wk, 3 wk, 4 wk)
  • changes in AI (Apathy Inventory)(baseline, at the end of treatment, 1wk, 2 wk, 3 wk, 4 wk)
  • changes in ADL (Activities of Daily Living)(baseline, at the end of treatment, 1wk, 2 wk, 3 wk, 4 wk)
  • changes in IADL (Instrumental Activities of Daily Living)(baseline, at the end of treatment, 1wk, 2 wk, 3 wk, 4 wk)
  • changes in QoL-AD (Quality of Life in Alzheimer's Disease)(baseline, at the end of treatment, 1wk, 2 wk, 3 wk, 4 wk)
  • changes in CP6 (Questionnaire of recent change in personnality)(baseline, at the end of treatment, 1wk, 2 wk, 3 wk, 4 wk)

Study Sites (1)

Loading locations...

Similar Trials